Description
Obatoclax is a BH3 mimetic and inhibitor of Bcl-2 and Bcl-xl that displays anti-metastatic and anticancer chemotherapeutic activities; it is currently in clinical trials as a potential treatment for various cancers. Obatoclax induces autophagy and apoptosis in adenoid cystic carcinoma cells and decreases tumor formation and growth in animal models of hepatoblastoma. In cellular models of colorectal cancer, obatoclax inhibits cell growth, induces G1 phase cell cycle arrest, and suppresses proliferation, migration, and invasion.